Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus
18F-fluciclovine PET/CT
EMPIRE-1 trial
adverse pathology
prostate cancer
prostate-specific antigen
salvage radiotherapy
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
23
08
2022
revised:
27
10
2022
medline:
5
4
2023
pubmed:
4
11
2022
entrez:
3
11
2022
Statut:
ppublish
Résumé
The EMPIRE-1 (Emory Molecular Prostate Imaging for Radiotherapy Enhancement 1) trial reported a survival advantage in recurrent prostate cancer salvage radiotherapy (SRT) guided by
Identifiants
pubmed: 36328489
pii: jnumed.122.264832
doi: 10.2967/jnumed.122.264832
pmc: PMC10071787
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Androgen Antagonists
0
fluciclovine F-18
38R1Q0L1ZE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
586-591Subventions
Organisme : NCI NIH HHS
ID : R01 CA169188
Pays : United States
Informations de copyright
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Eur Urol. 2019 Jun;75(6):896-900
pubmed: 30955970
J Nucl Med. 2021 Aug 1;62(8):1089-1096
pubmed: 33517323
Nucl Med Biol. 2015 Nov;42(11):887-92
pubmed: 26278491
Pract Radiat Oncol. 2019 Jul - Aug;9(4):208-213
pubmed: 31051281
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):316-324
pubmed: 32068113
Lancet Oncol. 2016 Jun;17(6):747-756
pubmed: 27160475
J Urol. 2022 Jul;208(1):10-18
pubmed: 35536144
Pract Radiat Oncol. 2020 Sep - Oct;10(5):354-362
pubmed: 32464368
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1046-1053
pubmed: 27745980
Nat Rev Urol. 2021 Nov;18(11):643-668
pubmed: 34363040
Int J Radiat Oncol Biol Phys. 2022 Aug 1;113(5):1003-1014
pubmed: 35417762
J Nucl Med. 2007 Jun;48(6):1017-20
pubmed: 17504867
Mol Imaging Biol. 2022 Feb;24(1):42-49
pubmed: 34480289
Nucl Med Biol. 2012 Jan;39(1):109-19
pubmed: 21958853
Urology. 2003 Mar;61(3):607-11
pubmed: 12639656
J Nucl Med. 2014 Dec;55(12):1986-92
pubmed: 25453047
Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3257-3268
pubmed: 35217883
J Nucl Med. 2020 Jun;61(6):866-872
pubmed: 31676727
Urology. 1996 Aug;48(2):249-60
pubmed: 8753737
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Am J Nucl Med Mol Imaging. 2021 Oct 15;11(5):406-414
pubmed: 34754611
Lancet. 2022 May 14;399(10338):1886-1901
pubmed: 35569466
J Clin Oncol. 2016 Oct 20;34(30):3648-3654
pubmed: 27528718
Lancet Oncol. 2019 Sep;20(9):1286-1294
pubmed: 31375469
BMC Cancer. 2019 Jan 7;19(1):18
pubmed: 30616601
Lancet. 2021 May 22;397(10288):1895-1904
pubmed: 33971152
J Nucl Med. 2017 Mar;58(3):412-418
pubmed: 27609792
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4463-4471
pubmed: 34091713
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83
pubmed: 27091135
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):104-11
pubmed: 22795730